Plain-English translation of NCT02234063 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hypertension research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial studied whether a genetic test called APOL1 testing could help prevent kidney disease in people with high blood pressure, particularly those of African ancestry. Researchers knew that African Americans with high blood pressure face a much higher risk of developing kidney disease compared to other groups. The trial tested whether knowing someone's genetic risk through APOL1 testing—combined with better blood pressure management—could help prevent this serious complication.
African Americans with high blood pressure are 2 to 3 times more likely to develop kidney disease than white Americans, and are at even higher risk of kidney failure. This trial was designed to see whether genetic information could help doctors catch and treat people at highest risk earlier, before kidney damage becomes severe.
Participants were randomly assigned to one of two groups. One group received the APOL1 genetic test right away when they joined the study, along with extra support from their doctors to manage blood pressure based on their genetic results. The other group waited and received the same genetic test at their final visit 12 months later. All participants attended regular visits and worked with their healthcare providers to manage their high blood pressure throughout the year-long study.
AI-generated summary from trial data · Oct 11, 2026 · Not medical advice
United States